thejapantimes, 23 days ago to Japan The writings of the monks Eisai and Dogen sought to determine the proper way to live on this Earth, in harmony with the Way. https://www.japantimes.co.jp/news/2024/05/17/japan/history/joy-zen-japanese-history/ #japan #history #zenbuddhism #dogen #eisai #kamakuraperiod
The writings of the monks Eisai and Dogen sought to determine the proper way to live on this Earth, in harmony with the Way. https://www.japantimes.co.jp/news/2024/05/17/japan/history/joy-zen-japanese-history/ #japan #history #zenbuddhism #dogen #eisai #kamakuraperiod
thejapantimes, 1 month ago to worldnews Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
thejapantimes, 4 months ago to business Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, according to a company spokesperson. https://www.japantimes.co.jp/business/2024/02/05/companies/eisai-alzheimers-drug-china/?utm_content=buffer2498b&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #business #companies #eisai #pharmaceuticals #alzheimer039s #china
Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, according to a company spokesperson. https://www.japantimes.co.jp/business/2024/02/05/companies/eisai-alzheimers-drug-china/?utm_content=buffer2498b&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #business #companies #eisai #pharmaceuticals #alzheimer039s #china
thejapantimes, 5 months ago to Japan New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. https://www.japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/?utm_content=buffer4dd52&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals
New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. https://www.japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/?utm_content=buffer4dd52&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals
thejapantimes, 9 months ago to Japan A health ministry panel reviewing the new Alzheimer’s drug lecanemab greenlighted its approval in Japan on Monday. https://www.japantimes.co.jp/news/2023/08/21/japan/science-health/lecanemab-alzheimers-drug-approval/?utm_content=buffer356e4&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #lecanemab #eisai #alzheimer039s #pharmaceuticals #health
A health ministry panel reviewing the new Alzheimer’s drug lecanemab greenlighted its approval in Japan on Monday. https://www.japantimes.co.jp/news/2023/08/21/japan/science-health/lecanemab-alzheimers-drug-approval/?utm_content=buffer356e4&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #lecanemab #eisai #alzheimer039s #pharmaceuticals #health
thejapantimes, 10 months ago to news Drug giant Eisai's global Alzheimer drug program officer Ivan Cheung will be replaced by the son of the firm’s CEO, after a tenure that saw Cheung lead the push for U.S. approval of breakthrough medicine Leqembi. https://www.japantimes.co.jp/news/2023/07/11/business/corporate-business/eisai-alzheimers-leqembi-ivan-cheung-ceo-son-keisuke-naito/?utm_content=bufferfeb39&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #corporate #pharmaceuticals #alzheimers #eisai #keisukenaito
Drug giant Eisai's global Alzheimer drug program officer Ivan Cheung will be replaced by the son of the firm’s CEO, after a tenure that saw Cheung lead the push for U.S. approval of breakthrough medicine Leqembi. https://www.japantimes.co.jp/news/2023/07/11/business/corporate-business/eisai-alzheimers-leqembi-ivan-cheung-ceo-son-keisuke-naito/?utm_content=bufferfeb39&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #corporate #pharmaceuticals #alzheimers #eisai #keisukenaito
thejapantimes, 11 months ago to news Eisai’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators, a move that will help widen insurance access to the first drug cleared based on its ability to slow progression of the mind-robbing disease. https://www.japantimes.co.jp/news/2023/07/07/world/science-health-world/eisai-alzherimers-drug-u-s-approval/?utm_content=buffer46a0b&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #worldnews #us #health #brain #alzheimers #eisai #medicine
Eisai’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators, a move that will help widen insurance access to the first drug cleared based on its ability to slow progression of the mind-robbing disease. https://www.japantimes.co.jp/news/2023/07/07/world/science-health-world/eisai-alzherimers-drug-u-s-approval/?utm_content=buffer46a0b&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #worldnews #us #health #brain #alzheimers #eisai #medicine
thejapantimes, 11 months ago to news Expectations for the Alzheimer's treatment lecanemab are rising in Japan and it could be approved as early as fall, but even then there would be several barriers to its widespread adoption. https://www.japantimes.co.jp/news/2023/07/04/national/science-health/lecanemab-japan-approval-expectations/?utm_content=bufferb2b8f&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #japan #aging #elderly #pharmaceuticals #dementia #alzheimers #eisai #medicine
Expectations for the Alzheimer's treatment lecanemab are rising in Japan and it could be approved as early as fall, but even then there would be several barriers to its widespread adoption. https://www.japantimes.co.jp/news/2023/07/04/national/science-health/lecanemab-japan-approval-expectations/?utm_content=bufferb2b8f&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #japan #aging #elderly #pharmaceuticals #dementia #alzheimers #eisai #medicine